Oncology Institute, Inc. TOI
We take great care to ensure that the data presented and summarized in this overview for Oncology Institute, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TOI
View all-
Vanguard Group Inc Valley Forge, PA4.55MShares$18 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.36MShares$13.3 Million0.22% of portfolio
-
Center Book Partners LP Greenwich, CT2.7MShares$10.7 Million0.51% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.52MShares$10 Million0.01% of portfolio
-
Kanen Wealth Management LLC Coral Springs, FL1.84MShares$7.31 Million2.15% of portfolio
-
Kent Lake Capital LLC Mill Valley, CA1.75MShares$6.95 Million0.37% of portfolio
-
Wexford Capital LP Greenwich, CT1.57MShares$6.24 Million0.86% of portfolio
-
Geode Capital Management, LLC Boston, MA1.4MShares$5.57 Million0.0% of portfolio
-
State Street Corp Boston, MA1.13MShares$4.49 Million0.0% of portfolio
-
Ubs Group Ag1.06MShares$4.19 Million0.0% of portfolio
Latest Institutional Activity in TOI
Top Purchases
Top Sells
About TOI
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Insider Transactions at TOI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 20
2025
|
Mohit Kaushal Director |
BUY
Grant, award, or other acquisition
|
Direct |
91,049
+15.63%
|
-
|
|
Nov 20
2025
|
Anne Mc George Director |
BUY
Grant, award, or other acquisition
|
Direct |
108,024
+16.69%
|
-
|
|
Nov 20
2025
|
Brad Hively Director |
BUY
Grant, award, or other acquisition
|
Direct |
74,074
+5.17%
|
-
|
|
Nov 20
2025
|
Mark L Pacala Director |
BUY
Grant, award, or other acquisition
|
Direct |
81,790
+14.72%
|
-
|
|
Nov 20
2025
|
Karen Marie Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
84,877
+13.69%
|
-
|
|
Nov 20
2025
|
Gabriel Ling Director |
BUY
Grant, award, or other acquisition
|
Direct |
83,333
+11.75%
|
-
|
|
Nov 18
2025
|
Mark L Pacala Director |
SELL
Open market or private sale
|
Direct |
50,000
-7.52%
|
$200,000
$4.0 P/Share
|
|
Nov 18
2025
|
M33 Growth I L.P. Director |
SELL
Other acquisition or disposition
|
Direct |
2,500,000
-31.47%
|
-
|
|
Nov 18
2025
|
M33 Growth I L.P. Director |
BUY
Other acquisition or disposition
|
Direct |
11,818
+0.15%
|
-
|
|
Nov 18
2025
|
M33 Growth I L.P. Director |
SELL
Other acquisition or disposition
|
Indirect |
590,892
-100.0%
|
-
|
|
Nov 18
2025
|
Gabriel Ling Director |
BUY
Other acquisition or disposition
|
Direct |
141,149
+36.07%
|
-
|
|
Nov 17
2025
|
Robert Ross Carter Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
195
+0.08%
|
-
|
|
Nov 17
2025
|
Yale Podnos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,086
+0.87%
|
-
|
|
Nov 17
2025
|
Daniel Virnich Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,464
+0.36%
|
-
|
|
Nov 12
2025
|
Yale Podnos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,508
+0.32%
|
-
|
|
Nov 12
2025
|
Daniel Virnich Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,211
+0.35%
|
-
|
|
Sep 04
2025
|
M33 Growth I L.P. Director |
SELL
Open market or private sale
|
Indirect |
681,832
-53.57%
|
$2,045,496
$3.09 P/Share
|
|
Sep 04
2025
|
M33 Growth I L.P. Director |
SELL
Open market or private sale
|
Direct |
6,018,168
-43.14%
|
$18,054,504
$3.09 P/Share
|
|
Aug 19
2025
|
Brad Hively Director |
SELL
Open market or private sale
|
Direct |
20,221
-3.14%
|
$80,884
$4.06 P/Share
|
|
Jul 24
2025
|
Richard A Barasch Director |
SELL
Other acquisition or disposition
|
Indirect |
287,756
-9.84%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 5.01M shares |
|---|---|
| Conversion of derivative security | 780K shares |
| Open market or private purchase | 1.54M shares |
| Exercise of in-the-money or at-the-money derivatives securities | 679K shares |
| Exercise of conversion of derivative security | 1.87M shares |
| Other acquisition or disposition | 153K shares |
| Payment of exercise price or tax liability | 311K shares |
|---|---|
| Other acquisition or disposition | 3.38M shares |
| Sale (or disposition) back to the issuer | 44.1K shares |
| Open market or private sale | 11.5M shares |